These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11869699)

  • 41. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Melphalan hypoxic perfusion with hemofiltration for melanoma locoregional metastases in the pelvis.
    Guadagni S; Fiorentini G; Clementi M; Palumbo G; Chiominto A; Cappelli S; Masedu F; Valenti M
    J Surg Res; 2017 Jul; 215():114-124. PubMed ID: 28688635
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
    Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
    Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
    Brady MS; Brown K; Patel A; Fisher C; Marx W
    Ann Surg Oncol; 2006 Aug; 13(8):1123-9. PubMed ID: 16791448
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
    Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.
    Koops HS; Vaglini M; Suciu S; Kroon BB; Thompson JF; Göhl J; Eggermont AM; Di Filippo F; Krementz ET; Ruiter D; Lejeune FJ
    J Clin Oncol; 1998 Sep; 16(9):2906-12. PubMed ID: 9738557
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
    Murata S; Onozawa S; Sugihara F; Sakamoto A; Ueda T; Yamaguchi H; Yasui D; Mine T; Kumita S
    Ann Surg Oncol; 2015 Nov; 22(12):3981-9. PubMed ID: 25758191
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase II study of regional chemotherapy using the hypoxic abdominal perfusion technique in advanced abdominal carcinoma. 5-FU pharmacokinetics, complications and outcome.
    Pohlen U; Rieger H; Kunick-Pohlen S; Berger G; Buhr HJ
    Anticancer Res; 2007; 27(1B):667-74. PubMed ID: 17348458
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Arterial infusion of dacarbazine and cisplatin for recurrent regionally confined melanoma.
    Frost DB; Patt YZ; Mavligit G; Chuang VP; Wallace S
    Arch Surg; 1985 Apr; 120(4):478-80. PubMed ID: 4039130
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
    Hoekstra HJ; Veerman K; van Ginkel RJ
    J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
    Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
    Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the efficacy and toxicity of upper extremity isolated limb infusion chemotherapy for melanoma: An Australian multi-center study.
    Kroon HM; Coventry BJ; Henderson MA; Barbour A; Serpell J; Smithers BM; Thompson JF
    Eur J Surg Oncol; 2019 May; 45(5):832-837. PubMed ID: 30867095
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Regional chemotherapy--perfusion of the extremities].
    Meyer T; Göhl J
    Kongressbd Dtsch Ges Chir Kongr; 2001; 118():200-4. PubMed ID: 11824246
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.
    Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; Hart AA
    Surgery; 1994 Jan; 115(1):39-45. PubMed ID: 8284759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypoxic pelvic perfusion with cisplatin and mitomycin C in multidisciplinary palliative treatment of patients with unresectable recurrent rectal cancer: a retrospective study.
    Guadagni S; Fiorentini G; Palumbo P; Masedu F; Ricevuto E; Bruera G; Deraco M; Kusamura S; Sarti D; Fiorentini C; Gailhofer S; Clementi M
    Minerva Chir; 2019 Aug; 74(4):304-312. PubMed ID: 31062943
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Melanoma recurrence confined to a free flap after isolated limb perfusion.
    Roberts CE; Harris PA; Thomas JM
    J Plast Reconstr Aesthet Surg; 2009 Aug; 62(8):e277-9. PubMed ID: 18463014
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma.
    Middleton MR; Lorigan P; Owen J; Ashcroft L; Lee SM; Harper P; Thatcher N
    Br J Cancer; 2000 Mar; 82(6):1158-62. PubMed ID: 10735499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Isolated hyperthermic limb perfusion with melphalan and tumor necrosis factor in malignant melanoma].
    Kettelhack C; Hohenberger P; Schlag PM
    Dtsch Med Wochenschr; 1997 Feb; 122(7):177-81. PubMed ID: 9072487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Surgical treatment and regional chemotherapy in melanoma of the extremities].
    Henneking K; Binder J; Weyers W; Schwemmle K
    Chirurg; 1993 Feb; 64(2):134-8. PubMed ID: 8462350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.